Ferroptosis-centered Drug Response Information

General Information of the Drug (ID: ferrodrug0131)
Name
Flubendazole
Synonyms
Flubendazole; 31430-15-6; Flumoxane; Flubendazol; Fluvermal; Flubenol; Methyl (5-(4-fluorobenzoyl)-1H-benzo[d]imidazol-2-yl)carbamate; Flubendazolum; Flumoxanal; R 17,889; Methyl 5-(p-fluorobenzoyl)-2-benzimidazolecarbamate; Flubendazole D3; NSC 313680; Methyl [5-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]carbamate; R 17899; NSC-313680; (5-(4-Fluorobenzoyl)-1H-benzimidazole-2-yl)carbamic acid methyl ester; Carbamic acid, (5-(4-fluorobenzoyl)-1H-benzimidazol-2-yl)-, methyl ester; Methyl N-(5-(p-fluorobenzoyl)-2-benzimidazolyl)carbamate; CHEBI:77095; methyl N-[6-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]carbamate; R8M46911LR; R-17889; R-17,889; NSC313680; CPD000466360; methyl N-{5-[(4-fluorophenyl)carbonyl]-1H-1,3-benzodiazol-2-yl}carbamate; Flubendazol [INN-Spanish]; Flubendazolum [INN-Latin]; SMR000466360; CCRIS 4480; SR-01000759412; EINECS 250-624-4; Flicum; UNII-R8M46911LR; Flubendazole [USAN:INN:BAN]; methyl {6-[(4-fluorophenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate; MFCD00871999; Flubendazole (Flutelmium); FLUBENDAZOLE [MI]; 2-BENZIMIDAZOLECARBAMIC ACID, 5-(p-FLUOROBENZOYL)-, METHYL ESTER; Flubendazole (USAN/INN); FLUBENDAZOLE [INN]; FLUBENDAZOLE [USAN]; FLUBENDAZOLE [MART.]; MLS000759477; MLS001424042; MLS006010905; FLUBENDAZOLE [WHO-DD]; SCHEMBL167185; CHEMBL1454946; DTXSID8023058; CPEUVMUXAHMANV-UHFFFAOYSA-N; Flubendazole for system suitability; HMS2051A18; HMS2090I16; HMS3393A18; HMS3714D06; FLUBENDAZOLE [EP MONOGRAPH]; BCP34258; HY-B0294; s1837; AKOS015894917; AKOS015960439; AC-8716; CCG-100887; CCG-267614; DB08974; NC00137; NCGC00246966-01; NCGC00246966-03; NCGC00246966-12; AS-12271; F0825; FT-0626436; D04200; D70276; AB00639981-06; AB00639981-08; AB00639981_09; EN300-7361973; Flubendazol, VETRANAL(TM), analytical standard; A820846; Q241992; Flubendazole, Antibiotic for Culture Media Use Only; Q-201119; SR-01000759412-4; SR-01000759412-5; Methyl [5-(4-Fluorobenzoyl)benzimidazol-2-yl]carbamate; Z2037280409; Flubendazol, European Pharmacopoeia (EP) Reference Standard; methyl 5-(4-fluorobenzoyl)-1H-benzo[d]imidazol-2-ylcarbamate; methyl N-[5-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]carbamate; [5-(4-Fluorobenzoyl)benzimidazol-2-yl]carbamic Acid Methyl Ester; Methyl (5-(4-fluorobenzoyl)-1H-benzo-[d]imidazol-2-yl)carbamate; methyl (6-(4-fluorobenzoyl)-1H-benzo[d]imidazol-2-yl)carbamate; methyl N-[5-(4-fluorobenzoyl)-1H-1,3-benzodiazol-2-yl]carbamate; Carbamicacid, [5-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]-methylester; N-{5-[(4-Fluorophenyl)carbonyl]benzimidazol-2-yl}methyloxymethanamide; Carbamic acid, N-[5-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]-, methyl ester; Flubendazole for system suitability, European Pharmacopoeia (EP) Reference Standard; N-[6-[(4-fluorophenyl)-oxomethyl]-1H-benzimidazol-2-yl]carbamic acid methyl ester; NSC 313680; NSC313680; NSC-313680; R 17899; R17899; R-17899

    Click to Show/Hide
Status
Investigative
Drug Type
Small molecular drug
Structure
Formula
C16H12FN3O3
IUPAC Name
methyl N-[6-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]carbamate
Canonical SMILES
COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=C(C=C3)F
InChI
InChI=1S/C16H12FN3O3/c1-23-16(22)20-15-18-12-7-4-10(8-13(12)19-15)14(21)9-2-5-11(17)6-3-9/h2-8H,1H3,(H2,18,19,20,22)
InChIKey
CPEUVMUXAHMANV-UHFFFAOYSA-N
PubChem CID
35802
Full List of Ferroptosis Target Related to This Drug
Unspecific Target
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Responsed Disease Prostate cancer ICD-11: 2C82
 Disease Info 
Responsed Regulator Cellular tumor antigen p53 (TP53) Driver
 Regulator Info 
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Apoptosis hsa04210
Cell Process Cell ferroptosis
Cell proliferation
Cell apoptosis
In Vitro Model PC-3 cells Prostate carcinoma Homo sapiens CVCL_0035
DU145 cells Prostate carcinoma Homo sapiens CVCL_0105
L-02 cells Endocervical adenocarcinoma Homo sapiens CVCL_6926
RWPE-1 cells Normal Homo sapiens CVCL_3791
In Vivo Model
24 nude mice (3-4 weeks) were acquired from the experimental animal center of southern medical university (GuangZhou, China) and kept under specific pathogen-free conditions. 4 x 106 PC3 cells were implanted subcutaneously into the right armpit regions of each nude mouse. When the tumors volume reached approximately 40 mm3, mice were randomly divided into two groups to receive flubendazole (10 mg/kg, once daily), 5-fluorouracil (30 mg/kg, once daily), their combination, and vehicle control by intraperitoneal injection. After 20 days of treatment, all mice were sacrificed and tumor weight and tumor volume were immediately measured, respectively.

    Click to Show/Hide
Response regulation Flubendazole is a novel P53 inducer which exerts anti-proliferation and pro-apoptosis effects in castration-resistant prostate cancer (CRPC) through hindering the cell cycle and activating the ferroptosis, and indicates that a novel utilization of flubendazole in neoadjuvant chemotherapy of CRPC.
References
Ref 1 Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer. Pharmacol Res. 2021 Feb;164:105305. doi: 10.1016/j.phrs.2020.105305. Epub 2020 Nov 14.